Literature DB >> 20686960

Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy.

Dean A Lee1, Michael R Verneris, Dario Campana.   

Abstract

Human natural killer (NK) cells, a subset of peripheral blood lymphocytes that lack a T- or B-cell receptor, play a crucial role in the innate immune response to viruses and malignant cells. NK cells differentiate infected or malignant cells from normal cells by a complex balance between activating and inhibitory receptor-ligand interactions. Unlike T cells, NK cells do not proliferate in vitro in response to simple crosslinking of a single activating receptor. While many methods to study T-cell function and phenotype can also be applied to NK cells, this chapter addresses methods that are unique to the preparation and assessment of human NK cells for immunotherapy.

Entities:  

Mesh:

Year:  2010        PMID: 20686960     DOI: 10.1007/978-1-60761-786-0_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

1.  Natural killer cell engineering for cellular therapy of cancer.

Authors:  D R Shook; D Campana
Journal:  Tissue Antigens       Date:  2011-12

2.  Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.

Authors:  Stefan O Ciurea; Jolie R Schafer; Roland Bassett; Cecele J Denman; Kai Cao; Dana Willis; Gabriela Rondon; Julianne Chen; Doris Soebbing; Indreshpal Kaur; Alison Gulbis; Sairah Ahmed; Katayoun Rezvani; Elizabeth J Shpall; Dean A Lee; Richard E Champlin
Journal:  Blood       Date:  2017-08-23       Impact factor: 22.113

Review 3.  Ex vivo gene transfer for improved adoptive immunotherapy of cancer.

Authors:  Minhtran C Ngo; Cliona M Rooney; Jeffrey M Howard; Helen E Heslop
Journal:  Hum Mol Genet       Date:  2011-03-17       Impact factor: 6.150

4.  Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins.

Authors:  Meisam Naeimi Kararoudi; Hamid Dolatshad; Prashant Trikha; Syed-Rehan A Hussain; Ezgi Elmas; Jennifer A Foltz; Jena E Moseman; Aarohi Thakkar; Robin J Nakkula; Margaret Lamb; Nitin Chakravarti; K John McLaughlin; Dean A Lee
Journal:  J Vis Exp       Date:  2018-06-14       Impact factor: 1.355

5.  Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV.

Authors:  Meisam Naeimi Kararoudi; Shibi Likhite; Ezgi Elmas; Kenta Yamamoto; Maura Schwartz; Kinnari Sorathia; Marcelo de Souza Fernandes Pereira; Yasemin Sezgin; Raymond D Devine; Justin M Lyberger; Gregory K Behbehani; Nitin Chakravarti; Branden S Moriarity; Kathrin Meyer; Dean A Lee
Journal:  Cell Rep Methods       Date:  2022-06-13

6.  Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.

Authors:  Natalia Lapteva; April G Durett; Jiali Sun; Lisa A Rollins; Leslie L Huye; Jian Fang; Varada Dandekar; Zhuyong Mei; Kimberley Jackson; Juan Vera; Jun Ando; Minhtran C Ngo; Elaine Coustan-Smith; Dario Campana; Susann Szmania; Tarun Garg; Amberly Moreno-Bost; Frits Vanrhee; Adrian P Gee; Cliona M Rooney
Journal:  Cytotherapy       Date:  2012-08-17       Impact factor: 5.414

7.  The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.

Authors:  Daniel W Lee; David M Barrett; Crystal Mackall; Rimas Orentas; Stephan A Grupp
Journal:  Clin Cancer Res       Date:  2012-05-15       Impact factor: 12.531

Review 8.  NK cell-based cancer immunotherapy: from basic biology to clinical development.

Authors:  Sizhe Liu; Vasiliy Galat; Yekaterina Galat; Yoo Kyung Annie Lee; Derek Wainwright; Jennifer Wu
Journal:  J Hematol Oncol       Date:  2021-01-06       Impact factor: 17.388

9.  Characterization and ex vivo Expansion of Human Placenta-Derived Natural Killer Cells for Cancer Immunotherapy.

Authors:  Lin Kang; Vanessa Voskinarian-Berse; Eric Law; Tiffany Reddin; Mohit Bhatia; Alexandra Hariri; Yuhong Ning; David Dong; Timothy Maguire; Martin Yarmush; Wolfgang Hofgartner; Stewart Abbot; Xiaokui Zhang; Robert Hariri
Journal:  Front Immunol       Date:  2013-05-01       Impact factor: 7.561

10.  Advances in clinical NK cell studies: Donor selection, manufacturing and quality control.

Authors:  U Koehl; C Kalberer; J Spanholtz; D A Lee; J S Miller; S Cooley; M Lowdell; L Uharek; H Klingemann; A Curti; W Leung; E Alici
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.